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P U B L I S H E D B Y E L S E V I E R I N C .LettersLeft Atrial Thrombus
Formation After
Successful Left Atrial
Appendage Ligation
Case Series From a Nationwide SurveyPercutaneous left atrial appendage (LAA) exclusion
can be performed using endocardial occlusion devices
or an endoepicardially placed suture delivery device
(1–3). Thrombus formation on endocardial occlusion
devices (Watchman, Boston Scientiﬁc, Marlborough,
Massachusetts; or Amplatzer Cardiac Plug [ACP],
St. Jude Medical, St. Paul, Minnesota) (1,2) has been
attributed to platelet aggregation in the setting of a
foreign body in the left atrium (LA). With the percu-
taneous endoepicardial ligation technique (Lariat,
SentreHEART, Redwood City, California), there is no
foreign body left behind, and the risk of thrombus
formation should be insigniﬁcant. This study de-
scribes the clinical course of LA thrombi after the
Lariat procedure in 19 patients.
We conducted a nationwide survey of physicians
performing procedures with the Lariat device in the
United States to identify patients who developed LA
thrombus after the procedure. Our study cohort
comprised patients found to have LA thrombus post-
procedure.
Post-procedure surveillance imaging was not uniform
across centers. Most patients underwent transesophageal
echocardiogram (TEE)/computed tomography at 1 to
3 months post-procedure. Anticoagulation/antiplatelet
therapy was initiated immediately after detection of
LA thrombus. We collected demographic, clinical, and
pre-procedural imaging characteristics of patients.
Procedural variables and clinical course of patients
after thrombus detection were recorded. Statistical
analyses were performed using SPSS version 19.0 for
Windows (SPSS, Inc., Chicago, Illinois).
A total of 47 operators participated in the survey.
Routine post-procedure imaging was performed by 44
(93.6%) operators. Three (6.4%) operators performed
imaging only if clinically indicated. Routine post-
procedure follow-up imaging was performed at 1 to
3 months and 3 to 6 months by 80% and 40% of theoperators, respectively. Of the 964 patients who un-
derwent the procedure, 19 (2%) had an LA thrombus.
Table 1 lists some patient characteristics and includes
follow-up data of the 19 patients.
LA thrombus was detected within 90 days in 15
(79%) patients. TEEs performed in the ﬁrst 6 months
were negative for thrombi in 2 patients with clots
discovered >200 days after the procedure. Eighteen
patients received oral anticoagulants after detection
of LA thrombus, whereas 1 patient received anti-
platelet therapy. Thrombus remained unchanged at
90 days in the latter patient, requiring a switch to
rivaroxaban. Serial TEEs were performed until
thrombus resolution. Oral anticoagulation was dis-
continued in 16 patients after clot resolution, whereas
3 patients with unresolved thrombi remained on
anticoagulation (30, 58, and 80 days, respectively).
None of the patients had clinical evidence of stroke or
peripheral embolism during follow-up.
Our study highlights that the risk of LA thrombus
formation with the device is low (2%). Most (79%)
cases were detected within the ﬁrst 90 days. Prompt
initiation of anticoagulation can lead to thrombus
resolution. This is the ﬁrst investigation to describe
the clinical course of LA thrombus post-procedure in
a large cohort of patients receiving the Lariat device.
In a clinical study involving 89 patients, no case of LA
thrombus was detected on the 30-day post-procedure
TEE. However, 1 patient had an LA thrombus
away from the site of occlusion at 1-year follow-up
(3). Our study is consistent in that, although un-
common, an LA thrombus can develop after the
procedure.
The pathophysiology of LA thrombus formation
after the Lariat procedure remains unclear. Focal
endocardial damage and inﬂammation around the
LAA oriﬁce secondary to tissue compression from the
Lariat suture, causing edema and ischemic necrosis
around the ligation site, can increase the propensity
for LA thrombus formation. In our study, 17 of 19 (89%)
patients developed a thrombus at the ligation site.
Currently, there are no clear guidelines on LA
thrombus surveillance after LAA ligation. We
strongly support a follow-up TEE 30 to 90 days
post-procedure. Given that the risk of thrombus
formation is greatest during the ﬁrst 3 months post-
procedure, it may be appropriate for patients to
TABLE 1 Patient Characteristics and Follow-Up (n ¼ 19)
Age, yrs 73.6  7.4
Male 13 (68.4)
Mean CHADS2 score 3.1  1.1
Mean CHA2DS2-VASc score 4.5  1.4
Mean HAS-BLED score 4.1  1.3
Post-Lariat anticoagulation* 1 (5.3)
Post-Lariat antiplatelet agents 4 (21.1)
Median time to clot detection, days 46 (17–428)
Location of clot
Endocardial surface of the ligated site 17 (89.5)
Coumadin ridge 1 (5.3)
Within the LAA through the leak into the LA 1 (5.3)
Average clot size, mm 11  10
Anticoagulation started 19 (100)
Warfarin 7 (36.9)
Novel oral anticoagulants† 12 (63.2)
Clot resolution‡ 16 (84.2)
Mean time to clot resolution, days 91 (34–228)
Clinical stroke or thromboembolism 0 (0)
Major bleeding during follow-up 0 (0)
Minor bleeding during follow-up 1 (5.5)
Values are mean  SD, n (%), or median (range). *One patient was on oral anti-
coagulation but was noncompliant. †One patient was on antiplatelet agents but
was switched to novel oral anticoagulants. ‡Three patients are still in follow-up.
CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, dia-
betes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74
years, sex category; CHADS2 score ¼ congestive heart failure, hypertension, age
$75 years, diabetes mellitus, stroke/transient ischemic attack; HAS-BLED ¼ hy-
pertension, abnormal renal/liver function, stroke, bleeding history or predisposi-
tion, labile international normalized ratio, elderly (>65 years), drugs/alcohol
concomitantly; LA ¼ left atrium; LAA ¼ left atrial appendage.
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1596receive antiplatelet or anticoagulant therapy during
this period.
The risk of LA thrombus in the absence of anti-
coagulation use post-procedure is low and is more
frequently seen during the ﬁrst 3 months after LAA
ligation. Periodic imaging studies are essential for
early detection of an LA thrombus. With prompt
initiation of anticoagulation and close supervision, an
LA thrombus can be managed safely.*Dhanunjaya Lakkireddy, MD
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Ischemic Heart Disease
Meet the Needs of Those
With Ischemia?Since 1990, multiple randomized clinical trials (RCTs)
and subsequent meta-analyses have compared the
outcome of percutaneous coronary intervention (PCI)
medical therapy for stable ischemic heart disease with
no difference in primary outcome (death and/or
myocardial infarction [MI]) between the 2 approaches.
The reasons for this are not clear. It is certainly possible
that there is no difference between the 2 strategies;
alternatively, the patient populations may not have
been appropriate, or the study hypothesis may not
have been sufﬁciently focused on the right question.
From 1980 until now, approximately 195,213 pa-
tients have been screened for enrollment in trials, of
